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Abstract: INTRODUCTION Cocaine abuse is a relevant public health issue which causes medical, psy-
chological and social drawbacks. Only limited data are currently available on outcomes of acute coronary
syndromes (ACS) in cocaine-addicted patients. The aim of this study was to evaluate the cardiovascular
impact of cocaine in a population of patients enrolled in the Swiss nationwide AMIS Plus registry, with
a focus on in-hospital outcomes. METHODS We retrospectively analysed data of patients enrolled in
the Swiss AMIS Plus registry from 1 January 2007 to 31 December 2018. Baseline and in-hospital data
of ACS patients with self-reported regular cocaine abuse were compared with the remaining AMIS Plus
population and a sex and age-matched group of non-cocaine user ACS patients (ratio 1:5, 540 patients).
Primary endpoints were in-hospital death and major adverse cardiac and cardiovascular events (MAC-
CEs). RESULTS A total of 20,036 patients were included in the AMIS Plus registry for ACS in the
study period, of whom 110 (0.5%) reported regular cocaine abuse. As compared with the remaining
AMIS population, cocaine users were significantly younger (46.4 ± 10.8 vs 66.4 ± 13.2 years, p lt;0.001),
presented more frequently with out-of-hospital cardiac arrest (11.8% vs 4.7%, p lt;0.001) and ST-elevation
myocardial infarction (68.2% vs 54.7%, p = 0.007). Of the traditional cardiovascular risk factors, there
was a higher incidence of positive family history and active smoking, but a lower incidence of arterial
hypertension, diabetes and obesity. In-hospital mortality (3.6% vs 4.4%, p = 1) and MACCEs (5.4% vs
5.5%, p = 0.83) were comparable. When compared with an age-matched non-cocaine user ACS popula-
tion, cocaine users were more frequently smokers (87.6% vs 63.6%, p lt;0.001) but less frequently obese
(10.4% vs 25.6%, p = 0.001). Clinical presentation was comparable between the two groups. However,
cocaine abuse was associated with a higher incidence of in-hospital death (3.7% vs 0.7%, p lt;0.05) and
MACCEs (5.6% vs 1.3%, p lt;0.05). CONCLUSION Cocaine abuse increases the risk of mortality by a
factor of 5 and the risk of major adverse cardiac and cardiovascular events by a factor of 4 as compared
with a sex and age-matched population hospitalised after an acute coronary syndrome.
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Summary
INTRODUCTION: Cocaine abuse is a relevant public
health issue which causes medical, psychological and so-
cial drawbacks. Only limited data are currently available
on outcomes of acute coronary syndromes (ACS) in co-
caine-addicted patients. The aim of this study was to eval-
uate the cardiovascular impact of cocaine in a population
of patients enrolled in the Swiss nationwide AMIS Plus
registry, with a focus on in-hospital outcomes.
METHODS: We retrospectively analysed data of patients
enrolled in the Swiss AMIS Plus registry from 1 January
2007 to 31 December 2018. Baseline and in-hospital data
of ACS patients with self-reported regular cocaine abuse
were compared with the remaining AMIS Plus population
and a sex and age-matched group of non-cocaine user
ACS patients (ratio 1:5, 540 patients). Primary endpoints
were in-hospital death and major adverse cardiac and car-
diovascular events (MACCEs).
RESULTS: A total of 20,036 patients were included in the
AMIS Plus registry for ACS in the study period, of whom
110 (0.5%) reported regular cocaine abuse. As compared
with the remaining AMIS population, cocaine users were
significantly younger (46.4 ± 10.8 vs 66.4 ± 13.2 years,
p <0.001), presented more frequently with out-of-hospital
cardiac arrest (11.8% vs 4.7%, p <0.001) and ST-elevation
myocardial infarction (68.2% vs 54.7%, p = 0.007). Of the
traditional cardiovascular risk factors, there was a high-
er incidence of positive family history and active smoking,
but a lower incidence of arterial hypertension, diabetes
and obesity. In-hospital mortality (3.6% vs 4.4%, p = 1)
and MACCEs (5.4% vs 5.5%, p = 0.83) were comparable.
When compared with an age-matched non-cocaine user
ACS population, cocaine users were more frequently
smokers (87.6% vs 63.6%, p <0.001) but less frequently
obese (10.4% vs 25.6%, p = 0.001). Clinical presentation
was comparable between the two groups. However, co-
caine abuse was associated with a higher incidence of
in-hospital death (3.7% vs 0.7%, p <0.05) and MACCEs
(5.6% vs 1.3%, p <0.05).
CONCLUSION: Cocaine abuse increases the risk of mor-
tality by a factor of 5 and the risk of major adverse cardiac
and cardiovascular events by a factor of 4 as compared
with a sex and age-matched population hospitalised after
an acute coronary syndrome.
Keywords: acute coronary syndrome, cocaine, Swiss
AMIS Plus registry
Introduction
Cocaine is a plant-based illicit drug that is produced from
the extract of the South American Erythroxylon coca
plant’s leaves. Generally taken by nasal insufflation, co-
caine can also be injected or smoked in the crystal form
of crack. Examples of frequently seen effects are a sense
of wellbeing, euphoria and a self-perceived sensation of
improved physical and mental performance. From a Eu-
ropean perspective, cocaine consumption has a lifetime
prevalence of 5.1%, so one can assume that 17 million Eu-
ropean citizens will consume cocaine at least once during
their lifetime [1].
Recent data from the European Monitoring Centre for
drugs and drug addiction showed that four Swiss cities are
among the top ten cities in Europe for cocaine use [1],
indicating a worrying epidemic spread of this illicit drug
throughout Switzerland. Easy access and relatively low
cost have contributed towards making cocaine the most
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estimated consumption of about 14 kilograms every day
within its borders [2].
The cardiovascular effects of cocaine have been thorough-
ly evaluated and its association with acute myocardial in-
farction was documented more than 30 years ago by Cole-
man [3]. Several different mechanisms explain its
detrimental effects on the cardiovascular system. Cocaine
can induce coronary vasospasm and premature atheroscle-
rosis, promote intracoronary thrombosis and increase sym-
pathomimetic activity [4–11]. Despite the well-known as-
sociation and the burden of available evidence, obtaining
reliable data on this subset of patients, as well as guiding
therapeutic choices, is challenging given the difficulties in
identifying abusers and the lack of evidence regarding tai-
lored therapies because of the systematic exclusion of this
population from randomised trials. From a prognostic per-
spective, difficulties in obtaining data on illicit drug abuse
means that it is hard to reach any conclusions concerning
its deleterious effect or to derive risk stratification tools ca-
pable of predicting clinical outcomes.
Thus, the aim of this analysis was to evaluate the preva-
lence of self-reported cocaine abuse in the setting of acute
coronary syndromes (ACS) and the cardiovascular impact
of cocaine consumption in a population of patients enrolled
in the nationwide AMIS Plus Registry, with a particular fo-
cus on in-hospital outcomes.
Methods
AMIS (Acute Myocardial Infarction in Switzerland) Plus
is a nationwide prospective registry established in 1997,
which collects data of patients admitted in more than 80
Swiss hospitals with the final diagnosis of ST-segment el-
evation myocardial infarction (STEMI), non-STEMI and
(since 2000) unstable angina pectoris. Data is collected
through a standardised questionnaire containing more than
280 variables and completed by treating doctors or trained
nurses. Data collection is centralised at the Epidemiology,
Biostatistic and Prevention Institute of the University of
Zurich. All data are checked for completeness, plausibility
and consistency by the AMIS Plus Data Centre and treat-
ing physicians are consulted in the event of incomplete da-
ta. Since 2010, external monitoring is regularly performed
at randomly selected hospitals. The registry was approved
(NCT01305785) by the Swiss Federal Ethics Committee
for Clinical Studies the Swiss Board for Data Security
and the appropriate Cantonal Ethic Commissions (Nr -
KEK-ZH-Nr.20140210/StV-Nr.05/05). The study protocol
conforms to the ethical guidelines of the Declaration of
Helsinki. Details on the AMIS Plus registry have been de-
scribed previously [12, 13].
Data on self-reported cocaine consumption have been col-
lected since 2007. Patients were routinely questioned about
any substance abuse and classified by disclosure of cocaine
consumption. In suspect cases (e.g. out-of-hospital cardiac
arrest in young patients with a suggestive environment)
toxicological screening was performed when deemed nec-
essary by treating physicians, but this was not undertaken
routinely. For the present analysis we considered patients
enrolled in the registry between 1 January 2007 and 31 De-
cember 2018.
Baseline and in-hospital data of patients with ACS and co-
caine use were compared with the remaining AMIS Plus
population as well as a sex and age-matched ACS popu-
lation (ratio 1:5) without any history of cocaine consump-
tion.
Cardiovascular risk factors were defined as follows: smok-
er, if the patient was smoking at the time of the cardiovas-
cular event; alcohol consumption, if the patient was con-
suming more than one drink a day at least 4 days per week;
diabetes, hypertension and dyslipidaemia, if the patient
was under treatment or had been previously diagnosed by
a physician; positive family history, if a patient’s first-de-
gree relative had a ischaemic heart disease when younger
than 60 years; obesity, if the patient had a body mass index
≥30 kg/m2.
In-hospital outcomes were evaluated and defined as fol-
lows: cardiogenic shock as persistent hypotension (systolic
blood pressure <90 mm Hg) with clinical signs of severe
reduction in cardiac index; stroke or transient ischaemic at-
tack as any event due to ischaemic, thrombotic or haemor-
rhagic disturbance confirmed by a neurologist or imaging;
re-infarction: clinical signs or symptoms of ischaemia with
ECG changes indicative of new ischemia (new ST-changes
or new left bundle branch block and a new rise of biomark-
ers following the initial infarction; bleeding was recorded
if deemed clinically relevant by the individual physician
caring for the patient. Primary endpoints were in-hospital
death and major adverse cardiac and cardiovascular events
(MACCEs), the latter defined as the combined endpoint of
re-infarction, stroke and/or death, which means that if a pa-
tient presented after the ACS an in-hospital re-infarction or
stroke and then died, those were considered per definition
as a single MACCE.
Statistics
For the description of baseline patient characteristics and
in-hospital data according to cocaine consumption, contin-
uous normally distributed variables are expressed as mean
and standard deviation (SD) and compared using the Stu-
dent’s two-tailed unpaired t-test. For categorical variables,
results are presented as percentages and analysed using the
Pearson chi-square test or Fisher’s exact test as appropri-
ate. Continuous nonnormally distributed variables are ex-
pressed as medians and interquartile ranges (IQRs) and
analysed using the Mann– Whitney U test. In the event
of missing data, we fused n/N (number of patients with a
characteristic/number of patients with available data) in-
stead of an imputation procedure. A two-sided p-value less
than 0.05 was considered statistically significant.
To correct for baseline imbalances, we analysed a propen-
sity matched sample from the crude population. For the
computation of the propensity score, age and sex were in-
cluded in a nonparsimonious logistic regression with co-
caine consumption as the dependent variable. Matching
was performed in proportions of 1:5. The validity of logis-
tic regression was assessed using the Hosmer-Lemeshow
test. Propensity matching was performed using the pack-
age Matching in R.12 The IBM SPSS Statistics Version 25
(IBM Corp; Armonk, New York, USA) was used for other
statistical analyses.
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Results
A total of 20,981 patients with acute coronary syndromes
were included in the AMIS Plus registry from 1 January
2007 to 31 December 2018. Information on cocaine con-
sumption was available for 95.5% (n = 20,036) of patients.
One hundred and ten (0.5%) self-declared regular cocaine
consumption during hospitalisation. Figure 1 shows patient
flow in the registry including both the non-matched and the
matched population.
Figure 1: Flow-chart. ACS = acute coronary syndrome.
Patient characteristics
ACS patients reporting cocaine abuse (COC+) were sig-
nificantly younger (46.4 ± 10.8 vs 66.4 ± 13.2 years, p
<0.001) and almost exclusively males (94.6% vs 76.8%,
p < 0.001) as compared with the AMIS Plus non-cocaine
user population. In addition, self-reported alcohol con-
sumption, smoking habits and family history for cardiovas-
cular events were more frequent in cocaine-using patients.
On the other hand, cocaine-using patients showed a lower
incidence of traditional cardiovascular risk factors such as
arterial hypertension, diabetes and obesity (table 1). They
also had lower rates of a previous history of heart fail-
ure, peripheral vascular disease, cerebrovascular disease
and cancer. Out-of-hospital cardiac arrest (11.8% vs 4.7%,
p = 0.002) and STEMI (68.2% vs 54.7%, p = 0.007) were
significantly more frequent in cocaine users compared with
the remaining AMIS population. Acquired immunodefi-
ciency syndrome was significantly more frequent in the co-
caine group as compared with the remaining AMIS popu-
lation (8.3% vs 0.1%, p <0.001).
Acute treatment
As shown on table 2, acute medical treatment with anti-
platelet therapy, vasodilators and statins was similar for
both groups. Diuretics and beta-blockers were less fre-
quently prescribed for cocaine users, whereas vasopressors
(13% vs 6.7%, p = 0.019) were more frequently adopted.
Coronary angiography was performed in 88.2% of cocaine
users and in 82.1% of the remaining AMIS population,
with a numerical, borderline non-significant, difference be-
tween groups (p = 0.059); the extent of coronary artery dis-
Table 1: Baseline characteristics.
AMIS plus population Cocaine abusers p-value Propensity matched
population
Cocaine abusers p-value
n/N (%) 19,926 (99.5) 110 (0.5) 540 108
Female sex, (%) 5413/19,926 (27.2) 7/110 (6.4) <0.001 34/540 (6.3) 7/108 (6.5) 1
Age in years, mean (SD) 66.4 (13.2) 46.4 (10.8) <0.001 46.8 (10.3) 46.8 (10.4) 0.98
Resuscitation prior to admission n, (%) 939/19,926 (4.7) 13/110 (11.8) 0.002 39/540 (7.2) 13/108 (12.0) 0.12
STEMI, n (%) 10891/19,926 (54.7) 75/110 (68.2) 0.007 341/540 (63.1) 73/108 (67.6) 0.44
BMI (kg/m2) 27.1 (4.8) 25.8 (3.8) 0.002 27.7 (4.5) 25.8 (3.8) <0.001
Risk factors
– Family history, n (%) 5288/16,329 (32.4) 40/76 (52.6) <0.001 195/487 (40.0) 40/76 (52.6) 0.045
– Smoking, n (%) 6776/18,141 (37.4) 93/106 (87.7) <0.001 327/514 (63.6) 92/105 (87.6) <0.001
– Dyslipidaemia, n (%) 10906/17,950 (60.8) 49/95 (51.6) 0.07 273/497 (54.9) 49/94 (52.1) 0.65
– Hypertension (%) 12183/19,127 (63.7) 30/100 (30.0) <0.001 210/514 (40.9) 30/98 (30.6) 0.07
– Diabetes n,(%) 3910/19,347 (20.2) 6/106 (5.7) <0.001 60/525 (11.4) 6/104 (5.8) 0.11
– Obesity (BMI >30 kg/m2), n (%) 3873/17,741 (21.8) 10/97 (10.3) 0.006 124/485 (25.6) 10/96 (10.4) 0.001
– Regular alcohol intake, n (%) 3107/18,004 (17.3) 53/81 (65.4) <0.001 91/494 (18.4) 52/80 (65.0) <0.001
Previous stable angina pectoris, n (%) 3085/19,618 (15.7) 10/108 (9.3) 0.089 65/537 (12.1) 10/106 (9.4) 0.51
Previous AMI, n (%) 3376/19,621 (17.2) 13/108 (12.0) 0.2 53/537 (9.9) 12/106 (11.3) 0.6
Previous PCI, n (%) 3252/19,618 (16.6) 12/108 (11.1) 0.16 54/537 (10.1) 11/106 (10.4) 0.86
Previous CABG, n (%) 1005/19,618 (5.1) 0/108 (0) 0.007 3/537 (0.6) 0/106 1
Comorbidities
– Heart failure, n (%) 652/19,620 (3.3) 1/109 (0.9) 0.27 6/532 (1.1) 1/107 (0.9) 1
– Peripheral vascular disease, n (%) 973/19,620 (5.0) 3/109 (2.8) 0.38 9/532 (1.7) 3/107 (2.8) 0.43
Cerebrovascular disease n,(%) 1059/19,620 (5.4) 2/109 (1.8) 0.13 10/532 (1.9) 2/107 (1.9) 1
– Cancer diseases, n (%) 1084/19,620 (5.5) 1/109 (0.9) 0.032 9/532 (1.7) 1/107 (0.9) 1
– AIDS (stage C), n (%) 17/19,620 (0.1) 9/109 (8.3) <0.001 2/532 (0.4) 9/107 (8.4) <0.001
Ischaemic region anterior, n (%) 6910/19,924 (34.7) 53/110 (48.2) 0.004 226/540 (41.9) 51/108 (47.2) 0.34
AIDS = acquired immunodeficiency syndrome; AMI = acute myocardial infarction; BMI = body mass index; CABG = previous coronary artery bypass graft; PCI = percutaneous
coronary intervention; SD = standard deviation; STEMI = ST-elevation myocardial infarction
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ease was different with a prevalent single vessel disease
(p = 0.002) treated by percutaneous coronary intervention
during the index procedure in 96.9% of the cocaine users
as compared to 86.8% of the remaining AMIS population.
In-hospital outcomes
Cocaine addicted patients had a shorter hospital stay than
non-cocaine users (median 4 days, IQR 2–7 vs 5 days, IQR
2–8 days; p= 0.049). There was no difference between co-
caine users and the AMIS Plus population in terms of in-
hospital events rates, such as recurrent ischaemic episodes,
cardiogenic shock, re-infarction, bleeding or cerebrovascu-
lar events (table 3). In-hospital mortality (3.6% vs 4.4%,
p = 1) and MACCEs (5.5% vs 5.4%, p = 0.83) rates were
comparable between cocaine users and the entire cohort of
AMIS patients (fig. 2).
Propensity score matched population
After propensity score matching, 540 non-cocaine users
were selected from the AMIS Plus population. In line with
the general AMIS population, positive family history and
smoking were confirmed to be significantly more strongly
represented in the cocaine-using group. In addition, the
cocaine group showed a lower incidence of obesity and
a greater rate of reported alcohol consumption than the
age/sex-matched population. Details of other cardiovascu-
lar risks factors are listed in table 1. Apart from a higher
incidence of acquired immunodeficiency syndrome in co-
caine users (8.4% vs 0.4%, p <0.001), no differences were
observed among other significant comorbidities.
With regard to clinical presentation, incidence of out-of-
hospital cardiac arrest and STEMI were comparable be-
tween the cocaine users and the matched group, with ob-
Table 2: Therapies at admission and angiographic findings.
AMIS Plus
population
Cocaine abusers p-value Propensity matched pop-
ulation
Cocaine abusers p-value
n/N (%) 19,926 (99.5) 110 (0.5) 540 108
ASA, n (%) 19,056/19,849 (96.0) 106/110 (96.4) 1 527/539 (97.8) 104/108 (96.3) 0.32
P2Y12 inhibitor, n (%) 17,388/19,818 (87.7) 96/110 (87.3) 0.88 508/540 (94.1) 95/108 (88.0) 0.035
Beta-blocker, n (%) 11,586/19,694 (58.8) 40/109 (36.7) <0.001 314/536 (58.6) 69/107 (36.4) <0.001
Nitrate, n (%) 876/19,572 (44.8) 53/109 (48.6) 0.44 257/533 (48.2) 53/107 (49.5) 0.83
ACEI/ARB, n (%) 11,604/19,737 (58.8) 60/109 (55.0) 0.44 315/537 (58.7) 59/107 (55.1) 0.52
Diuretic, n (%) 3938/19,582 (20.1) 12/108 (11.1) 0.025 50/533 (9.4) 12/106 (11.3) 0.59
Statin, n (%) 15,525/19,740 (78.6) 80/109 (73.4) 0.2 445/538 (82.7) 79/107 (73.8) 0.041
Vasopressor, n (%) 1314/19,501 (6.7) 14/108 (13.0) 0.019 33/531 (6.2) 14/106 (13.2) 0.023
Thrombolysis, n (%) 278/19,912 (1.4) 2/110 (1.8) 0.67 6/540 (1.1) 2/108 (1.9) 0.67
Coronary angiography, n (%) 16,356/19,926 (82.1) 97/110 (88.2) 0.059 489/540 (90.6) 96/108 (88.9) 0.48
Angiographic findings N = 17,863 N = 106 <0.001 N = 523 N = 105 0.49
– One vessel, n (%) 6743 (37.7) 56 (52.8) 276 (52.8) 55 (52.4)
– Two vessels, n (%) 5155 (28.9) 31 (29.2) 124 (23.7) 31 (29.5)
– Three vessels, n (%) 5231 (29.3) 14 (13.2) 108 (20.7) 14 (13.3)
– No abnormality, n (%) 300 (1.7) 3 (2.8) 10 (1.9) 3 (2.9)
PCI, n (%) 15760/19926 (79.1) 96/110 (87.3) 0.059 480/540 (88.9) 95/108 (88.0) 0.48
PCI with stent, n (%) 14608/15713 (93.0) 83/96 (86.5) 0.025 446/480 (92.9) 83/95 (87.4) 0.094
Vessel treated N = 15,273 N = 96 0.002 N = 473 N = 95 0.009
– One vessel, n (%) 13,264 (86.8) 93 (96.9) 418 (88.4) 92 (96.8)
– Multiple vessels, n (%) 2009 (13.2) 3 (3.1) 55 (11.6) 3 (3.2)
LVEF N = 12129 N = 80 0.027 N = 378 N = 79 0.018
– <35%, n (%) 1008 (8.3) 7 (8.8) 22 (5.8) 7 (8.9)
– 35–50%, n (%) 4210 (34.7) 39 (48.8) 137 (36.2) 38 (48.1)
– >50%, n (%) 6910 (57.0) 34 (42.5) 219 (57.9) 34 (43.0)
ACEI = angiotensin-converting enzyme inhibitors; ASA = acetylsalicylic acid; ARB = angiotensin receptor blocker; LVEF = left ventricular ejection fraction; PCI = percutaneous
coronary intervention
Table 3: In-hospital outcomes.
AMIS Plus population Cocaine
abuseres
p-value Propensity matched popula-
tion
Cocaine abusers p-value
n/N (%) 19,926 (99.5) 110 (0.5) 540 108
Length of stay in days, median
(IQR)
5 (2–8) 4 (2–7) 0.049 4 (2–7) 4 (2–7) 0.66
Recurrent ischaemic episode,
n (%)
289/19,922 (1.5) 0/110 0.41 5/540 (0.9) 0/108 (0.0) 0.6
Cardiogenic shock, n (%) 620/19,920 (3.1) 3/110 (2.7) 1 9/540 (1.7) 3/108 (2.8) 0.43
Reinfarction, n (%) 160/19,922 (0.8) 2/110 (1.8) 0.22 2/540 (0.4 2/108 (1.9) 0.13
Bleeding, any, n (%) 679/19,922 (3.4) 4/110 (3.6) 0.79 15/540 (2.8) 4/108 (3.7) 0.54
Cerebrovascular event, n (%) 141/19,922 (0.7) 2/110 (1.8) 0.19 1/540 (0.2) 2/108 (1.9) 0.074
Mortality, n (%) 867/19,926 (4.4) 4/110 (3.6) 1 4/540 (0.7) 4/108 (3.7) 0.03
MACCE, n (%) 1075/19,922 (5.4) 6/110 (5.5) 0.83 7/540 (1.3) 6/108 (5.6) 0.012
IQR = interquartile range; MACCE = major adverse cardiac and cardiovascular event
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served rates of 12% and 7.2% (p = 0.12) and 67.6% and
63.1% (p = 0.44), respectively.
Immediate therapies and management
Cocain addicted patients received P2Y12 inhibitors, beta-
blockers and statins less frequently, but vasopressors were
more frequently used than in the matched population (table
2). Rates of coronary angiography and coronary interven-
tion were comparable between the two groups. The extent
of coronary artery disease did not differ significantly be-
tween cocaine users and matched controls.
In-hospital outcomes
No difference in the length of hospital stay was observed
after matching, with a median length stay of 4 days in both
groups. The same applied to rates of in-hospital events.
Concerning the primary endpoint, cocaine abusers showed
a mortality rate roughly 5 times higher and a MACCE rate
roughly 4 times higher than matched, non-cocaine users
(fig. 3 and table 3).
Discussion
The present analysis derived from the Swiss national reg-
istry on myocardial infarction (AMIS Plus) is, to the best
of our knowledge, one of the largest cohorts of cocaine
users presenting with acute coronary syndrome.
The main findings of the present analysis are as follows:
1. As compared with the remaining AMIS population,
regular cocaine users were significantly younger, with
fewer cardiovascular risk factors and presented more
frequently with out-of-hospital-cardiac arrest and
STEMI.
2. In-hospital mortality and MACCEs of regular cocaine
users were comparable to the general AMIS Plus pop-
ulation. Nonetheless, when compared with an age- and
sex-matched population, rates were increased by 5 and
4 times, respectively, highlighting the deleterious
prognostic impact of this substance abuse in the ACS
setting.
Our study differs from previous reports regarding the as-
sociation between cocaine and ACS. Firstly, our analysis
is based on a European population and secondly, results
of a propensity score analysis have been provided in order
to balance covariates between cocaine abusers and non-
abusers in the ACS setting.
Our analysis shows a prevalence of cocaine consumption
of in-hospital ACS patients of 0.5%. It is known that co-
caine is the second most widely consumed illicit drug in
Switzerland after cannabis, with a lifetime prevalence for
consumption of 4.2% and a 12-month prevalence of 0.7%
in the general population [14]. Cocaine intoxication is also
a major cause for attendance at emergency departments in
Switzerland [15, 16]. Our estimate clearly underrates the
prevalence of cocaine abusers among ACS patients, but it
can be confirmed that at least 1 out of 200 patients admit-
ted with ACS in Switzerland are cocaine users.
When observing the baseline characteristics of cocaine
users, the prototypal patient is a male in his fourth decade
of life with an otherwise low cardiovascular risk profile
when compared with the general AMIS population. Of
note, when compared with an age- and sex-matched popu-
lation, cocaine users showed a lower incidence of obesity,
were more frequently smokers and had a family history of
cardiovascular diseases. Interestingly, data on the national
analysis of drug consumption show that addiction decreas-
es with age, with a prevalence for cocaine consumption of
Figure 2: In-hospital mortality in overall AMIS population.
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6.0% for males aged 25–29, 1.6% in subjects aged 30–39
years and only 0.5% in the group aged 40–59 years [17].
This, in association with the evidence that the vast major-
ity of patients showed single vessel disease, emphasises
the fact that in the ACS setting, cocaine consumption acts
as a trigger against a background of pre-existing coronary
artery disease [18]. It is worth pointing out that a greater
incidence of alcohol consumption and human immunode-
ficiency virus disease is observed in this group of patients,
highlighting specific aspects of this population with a high-
er propensity for risky behaviour and polytoxicomania.
Our data, in line with previous analyses [19, 20], show
that ACS in cocaine users seems to be associated with a
higher rate of STEMI and out-of-hospital cardiac arrest
when compared with non-users. Additional variables, such
as smoking, which was more frequent in cocaine con-
sumers, might have played an additional role. This worse
clinical presentation is linked to a complex imbalance be-
tween myocardial oxygen demand/supply and the activa-
tion of platelet aggregation mediated by cocaine. Previous
work demonstrated how cocaine might deleteriously and
simultaneously act as a positive inotropic and chronotropic
agent, which increases myocardial oxygen demand [7], a
vasoconstrictor, which decreases myocardial oxygen sup-
ply [4, 8] including in healthy non-arteriosclerotic vessels
[18], and a platelet activator [5, 6].
Cocaine users were less likely to be prescribed beta-block-
ers when compared with the general AMIS population and
the matched group because of concerns about a poten-
tial alpha-adrenergic-mediated exacerbation of vasospasm
[21–24]. No difference in terms of referral for coronary
angiography or percutaneous treatment were observed be-
tween the groups, while cocaine users acutely showed a
moderate impairment of left ventricular function on
echocardiography.
In terms of in-hospital outcomes, no differences in mortal-
ity or MACCE rates were observed. In other words, out-
comes seen in cocaine users are comparable to those of a
much older (mean 20 years) ACS population with a sig-
nificantly greater burden of comorbidities. This deleteri-
ous impact is confirmed after propensity score matching.
ACS in cocaine users was in fact associated with a 5-fold
increase in in-hospital mortality and a 4-fold increase in
MACCEs as compared with an age- and sex-matched pop-
ulation. It is worth noting that the difference in the com-
posite endpoint of MACCEs (re-infarction, stroke and/or
death) was driven by deaths, with no statistical difference
in re-infarction and stroke rates.
This retrospective and registry-based analysis, as per study
design, is prone to intrinsic limitations. First of all, data on
cocaine consumption were based on voluntary disclosure
and toxicological screening was certainly not performed on
a routine basis on each patient enrolled in the registry. This
clearly underestimates the rate of cocaine users resulting in
selection bias, as well as underreporting. Furthermore, we
have no information on the timing of cocaine intake in re-
lation to the occurrence of symptoms or the frequency of
consumption. These are all factors that could influence the
risk of developing an ACS.
Association between cocaine and ACS may be influenced
by confounders such as the risk behaviour of cocaine users
(more inclined toward smoking, alcohol consumption and
HIV infection, which could be associated with the con-
sumption of others intravenous drugs). For the registry, fol-
low-up data are obtained by phone calls only for a limited
Figure 3: In-hospital mortality in matched cohort.
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number of patients. This means that reliable long-term fol-
low-up data cannot be provided for cocain-using patients.
In conclusion, data derived from the AMIS plus registry
show that cocaine users admitted with ACS are a specific
subgroup of patients of a younger age and a lower burden
of comorbidities than the general AMIS population. De-
spite their lower baseline risk, the clinical presentation and
in hospital outcomes of cocaine abusers are of concern
leading to a 5-fold increase in mortality as compared to an
age and sex matched population. This emphasises the clin-
ical importance of cocaine-related ACS and should sen-
sitise clinicians, patients and healthcare providers to this
issue and encourage the development of dedicated diag-
nostic pathways and prognostic scores.
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